611 related articles for article (PubMed ID: 24372927)
1. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
2. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
3. Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors.
Cerquozzi S; Tefferi A
Blood Cancer J; 2015 Nov; 5(11):e366. PubMed ID: 26565403
[TBL] [Abstract][Full Text] [Related]
4. Changing incidence of myeloproliferative neoplasms: trends and subgroup risk profiles in the USA, 1973-2011.
Deadmond MA; Smith-Gagen JA
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2131-8. PubMed ID: 25968903
[TBL] [Abstract][Full Text] [Related]
5. Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea.
Lim Y; Lee JO; Bang SM
J Korean Med Sci; 2016 Oct; 31(10):1579-85. PubMed ID: 27550486
[TBL] [Abstract][Full Text] [Related]
6. Epidemiology of the Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms.
Shallis RM; Zeidan AM; Wang R; Podoltsev NA
Hematol Oncol Clin North Am; 2021 Apr; 35(2):177-189. PubMed ID: 33641862
[TBL] [Abstract][Full Text] [Related]
7. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
8. MERGE: A Multinational, Multicenter Observational Registry for Myeloproliferative Neoplasms in Asia, including Middle East, Turkey, and Algeria.
Yassin MA; Taher A; Mathews V; Hou HA; Shamsi T; Tuğlular TF; Xiao Z; Kim SJ; Depei W; Li J; Rippin G; Sadek I; Siddiqui A; Wong RS
Cancer Med; 2020 Jul; 9(13):4512-4526. PubMed ID: 32351024
[TBL] [Abstract][Full Text] [Related]
9. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States.
Verstovsek S; Yu J; Scherber RM; Verma S; Dieyi C; Chen CC; Parasuraman S
Leuk Lymphoma; 2022 Mar; 63(3):694-702. PubMed ID: 34689695
[TBL] [Abstract][Full Text] [Related]
10. Incidence of myeloproliferative neoplasms in Calgary, Alberta, Canada.
Heppner J; Nguyen LT; Guo M; Naugler C; Rashid-Kolvear F
BMC Res Notes; 2019 May; 12(1):286. PubMed ID: 31126326
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia.
Johansson P
Semin Thromb Hemost; 2006 Apr; 32(3):171-3. PubMed ID: 16673273
[TBL] [Abstract][Full Text] [Related]
12. Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden.
Landgren O; Goldin LR; Kristinsson SY; Helgadottir EA; Samuelsson J; Björkholm M
Blood; 2008 Sep; 112(6):2199-204. PubMed ID: 18451307
[TBL] [Abstract][Full Text] [Related]
13. Current diagnostic criteria for the chronic myeloproliferative disorders (MPD) essential thrombocythemia (ET), polycythemia vera (PV) and chronic idiopathic myelofibrosis (CIMF).
Michiels JJ; Bernema Z; Van Bockstaele D; De Raeve H; Schroyens W
Pathol Biol (Paris); 2007 Mar; 55(2):92-104. PubMed ID: 16919893
[TBL] [Abstract][Full Text] [Related]
14. Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Kutti J; Ridell B
Pathol Biol (Paris); 2001 Mar; 49(2):164-6. PubMed ID: 11317963
[TBL] [Abstract][Full Text] [Related]
15. Epidemiology of myeloproliferative neoplasms in the United States.
Mehta J; Wang H; Iqbal SU; Mesa R
Leuk Lymphoma; 2014 Mar; 55(3):595-600. PubMed ID: 23768070
[TBL] [Abstract][Full Text] [Related]
16. Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017.
Htun HL; Lian W; Wong J; Tan EJ; Foo LL; Ong KH; Lim WY
Cancer Epidemiol; 2022 Aug; 79():102175. PubMed ID: 35569302
[TBL] [Abstract][Full Text] [Related]
17. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
18. JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms.
Duletić AN; Dekanić A; Hadzisejdić I; Kusen I; Matusan-Ilijas K; Grohovac D; Grahovac B; Jonjić N
Coll Antropol; 2012 Sep; 36(3):859-65. PubMed ID: 23213945
[TBL] [Abstract][Full Text] [Related]
19. Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.
Hultcrantz M; Ravn Landtblom A; Andréasson B; Samuelsson J; Dickman PW; Kristinsson SY; Björkholm M; Andersson TM
J Intern Med; 2020 Apr; 287(4):448-454. PubMed ID: 31927786
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of polycythemia vera and essential thrombocythemia.
Ma X; Vanasse G; Cartmel B; Wang Y; Selinger HA
Am J Hematol; 2008 May; 83(5):359-62. PubMed ID: 18181200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
